Immunomodulatory Biomaterials 2

Timeslot: Thursday, April 28, 2022 - 1:00pm to 2:30pm
Room: Harborside Ballroom D-E, 4th Floor

About

This session will focus on engineered biomaterials for modulate and regulate immune functions in the settings of autoimmune diseases, allergies, transplantation, cancer immunotherapies, etc. Specifically, the session will cover topic ranging from biomaterials for drug delivery of immunomodulators and imaging agents, antigen delivery, scaffolds for immunomodulation, microbiome modulation, cell-based therapies, etc. Cutting-edge immunoengineering platforms will be included.

Abstracts

Abstracts will be available for download on April 27, 2022.

  • 1:00:00 PM 197. Nanoparticle-Medi- ated Genetic Repro- gramming of Merkel Cell Carcinoma Leads to Immune Activation and Targeted Cancer Cell Killing in Vitro, Kathryn Luly, BS*, Jordan Green, PhD, Stephany Tzeng, PhD, Joel Sunshine, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

  • 1:15:00 PM 198. Multispectral Flow Cytometry Immune Response Characterization of ECM Scaffold Modified with STING Agonist, Rohan Chaudhari*, Matthew Wolf, PhD., Sanjay Pal, PhD., National Institute of Cancer, Frederick, MD, USA

  • 1:30:00 PM 199. Modulating the Biologic Scaffold Immune Microenvi- ronment with STING Agonists, Sanjay Pal, PhD*, Brenna Hill, PhD, Rohan Chaud- hari, BS, Matthew Wolf, PhD, National Cancer Institute, Frederick, MD, USA

  • 1:45:00 PM 200. Supramolecular Nanotherapeutics Enables Metabolic reprogramming of Tumor Associated Macrophages to Inhibit Tumor Growth, Anujan Ramesh*, Vaishaliv Malik, Ashish Kulkarni, University of Massachusetts Amherst, Amherst, MA, USA

  • 2:00:00 PM 201. Tissue Engineering Scaffolds for Minimally Invasive Immunosurveillance of Acute Cellular Allograft Rejection, Russell Urie, PhD*, Aaron Morris, PhD, Diana Farris, Elizabeth Lombard, Jun Li, PhD, Daniel Goldstein, MD, Lonnie Shea, PhD, University of Michigan, Ann Arbor, MI, USA

  • 2:15:00 PM 202. Rescue of Dendritic Cell Metabolism from Glycolysis Inhibition for Cancer Immunotherapy, Sahil Inamdar(1)*, Joslyn Mangal, Abhirami Suresh, Nathan ng, Alison Sundem, Marion Curtis, Abhinav Acharya, (1)Arizona State University, Tempe, AZ, USA